Published: 28. May, 2026
Cessatech today announced the interim report for the three months ended March 31, 2026….
Cessatech today announced the interim report for the three months ended March 31, 2026.
The Company has advanced well with its planned activities in Q1 2026
- Continued progress towards US launch of CT001
- Regulatory review progressing with EMA following MAA submission for CT001
- Clinical data from CT001 study 0202 presented at Society for Pediatric Pain Medicine (SPPM) 13th Annual Meeting
- Strengthened intellectual property portfolio with additional patents granted in key markets
Jes Trygved, CEO at Cessatech said:
“We continue to make solid progress advancing CT001 towards commercialisation, although CT001 has not yet entered the U.S. market as initially anticipated. The extended timeline reflects the additional time required to complete final manufacturing validation, stability studies and quality assurance activities prior to product release. Together with our partners, we remain focused on completing these final steps and advancing CT001 towards potential availability for pediatric patients in the U.S. and Europe. In addition, we also had the opportunity to join the Annual Pain Practice meeting in Denver, US (SPPM), to present Study 0202 from CT001, which was very well received.”
Link to Report: Q1-2026 Report
